76 related articles for article (PubMed ID: 21847473)
1. Pharmaceutical formulation affects titanocene transferrin interactions.
Buettner KM; Snoeberger RC; Batista VS; Valentine AM
Dalton Trans; 2011 Oct; 40(37):9580-8. PubMed ID: 21847473
[TBL] [Abstract][Full Text] [Related]
2. Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride.
Guo M; Sun H; McArdle HJ; Gambling L; Sadler PJ
Biochemistry; 2000 Aug; 39(33):10023-33. PubMed ID: 10955990
[TBL] [Abstract][Full Text] [Related]
3. Superstoichiometric Binding of the Anticancer Agent Titanocene Dichloride by Human Serum Transferrin and the Accompanying Lobe Closure.
Profitt LA; Baxter RHG; Valentine AM
Biochemistry; 2022 May; 61(9):795-803. PubMed ID: 35373558
[TBL] [Abstract][Full Text] [Related]
4. Calorimetric, spectroscopic, and model studies provide insight into the transport of Ti(IV) by human serum transferrin.
Tinoco AD; Incarvito CD; Valentine AM
J Am Chem Soc; 2007 Mar; 129(11):3444-54. PubMed ID: 17315875
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins.
Rudnev AV; Foteeva LS; Kowol C; Berger R; Jakupec MA; Arion VB; Timerbaev AR; Keppler BK
J Inorg Biochem; 2006 Nov; 100(11):1819-26. PubMed ID: 16938349
[TBL] [Abstract][Full Text] [Related]
6. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
[TBL] [Abstract][Full Text] [Related]
7. HPLC-ICPMS and stable isotope-labeled approaches to assess quantitatively Ti(IV) uptake by transferrin in human blood serum.
Sarmiento-González A; Ruiz Encinar J; Cantarero-Roldán AM; Marchante-Gayón JM; Sanz-Medel A
Anal Chem; 2008 Nov; 80(22):8702-11. PubMed ID: 18847283
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
Korfel A; Scheulen ME; Schmoll HJ; Gründel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
[TBL] [Abstract][Full Text] [Related]
9. Binding of V(IV) to human transferrin: potential relevance to anticancer activity of vanadocene dichloride.
Du H; Xiang J; Zhang Y; Tang Y; Xu G
J Inorg Biochem; 2008 Jan; 102(1):146-9. PubMed ID: 17825420
[TBL] [Abstract][Full Text] [Related]
10. A versatile approach for assaying in vitro metallodrug metabolism using CE hyphenated with ICP-MS.
Abramski JK; Foteeva LS; Pawlak K; Timerbaev AR; Jarosz M
Analyst; 2009 Oct; 134(10):1999-2002. PubMed ID: 19768206
[TBL] [Abstract][Full Text] [Related]
11. Ti(IV) binds to human serum transferrin more tightly than does Fe(III).
Tinoco AD; Valentine AM
J Am Chem Soc; 2005 Aug; 127(32):11218-9. PubMed ID: 16089431
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.
Piccioli F; Sabatini S; Messori L; Orioli P; Hartinger ChG; Keppler BK
J Inorg Biochem; 2004 Jun; 98(6):1135-42. PubMed ID: 15149825
[TBL] [Abstract][Full Text] [Related]
13. A new generation of anticancer drugs: mesoporous materials modified with titanocene complexes.
Pérez-Quintanilla D; Gómez-Ruiz S; Zizak Z; Sierra I; Prashar S; del Hierro I; Fajardo M; Juranić ZD; Kaluderović GN
Chemistry; 2009; 15(22):5588-97. PubMed ID: 19370742
[TBL] [Abstract][Full Text] [Related]
14. Antitumour bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives.
Abeysinghe PM; Harding MM
Dalton Trans; 2007 Aug; (32):3474-82. PubMed ID: 17680034
[TBL] [Abstract][Full Text] [Related]
15. Investigation on the interaction between tamoxifen and human holo-transferrin: determination of the binding mechanism by fluorescence quenching, resonance light scattering and circular dichroism methods.
Sarzehi S; Chamani J
Int J Biol Macromol; 2010 Nov; 47(4):558-69. PubMed ID: 20708639
[TBL] [Abstract][Full Text] [Related]
16. Contrasting synergistic anion effects in vanadium(V) binding to nicatransferrin versus human serum transferrin.
Gaffney JP; Valentine AM
Biochemistry; 2009 Dec; 48(49):11609-11. PubMed ID: 19921860
[TBL] [Abstract][Full Text] [Related]
17. A mass spectrometric and molecular modelling study of cisplatin binding to transferrin.
Khalaila I; Allardyce CS; Verma CS; Dyson PJ
Chembiochem; 2005 Oct; 6(10):1788-95. PubMed ID: 16196027
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies on the interaction between bovine beta-lacto-globulin type A and B and a new designed Pd(II) complex with anti-tumor activity at different temperatures.
Divsalar A; Saboury AA; Mansouri-Torshizi H; Moghaddam MI; Ahmad F; Hakimelahi GH
J Biomol Struct Dyn; 2009 Apr; 26(5):587-97. PubMed ID: 19236109
[TBL] [Abstract][Full Text] [Related]
19. Metallomics for drug development: serum protein binding and analysis of an anticancer tris(8-quinolinolato)gallium(III) drug using inductively coupled plasma mass spectrometry.
Ossipov K; Foteeva LS; Seregina IF; Perevalov SA; Timerbaev AR; Bolshov MA
Anal Chim Acta; 2013 Jun; 785():22-6. PubMed ID: 23764439
[TBL] [Abstract][Full Text] [Related]
20. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy.
Khalaila I; Bergamo A; Bussy F; Sava G; Dyson PJ
Int J Oncol; 2006 Jul; 29(1):261-8. PubMed ID: 16773208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
